New hope for liver cancer: drug combo targets tough cases

NCT ID NCT06309485

Recruiting now Disease control Sponsor: Zhejiang Haichang Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug, WGI-0301, combined with sorafenib in 60 adults with advanced liver cancer that cannot be removed by surgery and has not responded to prior immunotherapy. The goal is to find the best dose and see if the combination can shrink tumors. Participants must be at least 18 and have a confirmed diagnosis of hepatocellular carcinoma.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

China Pharmaceutical University, Shanghai Gobroad Cancer Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200131, China
Prince of Wales Hospital
NOT_YET_RECRUITING

Hong Kong, Hong Kong
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
RECRUITING

Hangzhou, China
West China Hospital Sichuan University
RECRUITING

Chengdu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.